Endocrine Abstracts

AimStudy the efficacy of empagliflozin effects on main cardiovascular risk factors in non-insulin-dependent diabetic patients with normal and excessive body weight.Objectives60 patients with type 2 diabetes who have been taking metformin for at least 6 months but haven’t reached the target level of glycated haemoglobin (HbA1c), as well as 10 healthy individuals were examined. Depending on the prescribed ...